Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. more
Time Frame | CRDF | Sector | S&P500 |
---|---|---|---|
1-Week Return | 45.95% | -1.44% | 0.14% |
1-Month Return | 9.25% | -3.08% | 1% |
3-Month Return | 65.07% | -7.09% | 10.23% |
6-Month Return | 28.14% | -1.54% | 12.9% |
1-Year Return | 195.31% | 8.85% | 30.94% |
3-Year Return | -32.74% | 7.52% | 28.43% |
5-Year Return | 188.55% | 44.8% | 93% |
10-Year Return | -98.81% | 107.75% | 198.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 245.00K | 365.99K | 359.00K | 386.00K | 488.00K | [{"date":"2019-12-31","value":50.2,"profit":true},{"date":"2020-12-31","value":75,"profit":true},{"date":"2021-12-31","value":73.57,"profit":true},{"date":"2022-12-31","value":79.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 11.16M | 11.23M | 500.00K | 200.00K | 32.86M | [{"date":"2019-12-31","value":33.97,"profit":true},{"date":"2020-12-31","value":34.19,"profit":true},{"date":"2021-12-31","value":1.52,"profit":true},{"date":"2022-12-31","value":0.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (10.92M) | (10.87M) | (141.00K) | 186.00K | 488.00K | [{"date":"2019-12-31","value":-2237.14,"profit":false},{"date":"2020-12-31","value":-2227.26,"profit":false},{"date":"2021-12-31","value":-28.89,"profit":false},{"date":"2022-12-31","value":38.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (4456.01%) | (2969.73%) | (39.28%) | 48.19% | 100.00% | [{"date":"2019-12-31","value":-4456.01,"profit":false},{"date":"2020-12-31","value":-2969.73,"profit":false},{"date":"2021-12-31","value":-39.28,"profit":false},{"date":"2022-12-31","value":48.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 16.92M | 19.45M | 29.21M | 40.29M | 45.90M | [{"date":"2019-12-31","value":36.87,"profit":true},{"date":"2020-12-31","value":42.38,"profit":true},{"date":"2021-12-31","value":63.65,"profit":true},{"date":"2022-12-31","value":87.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (16.68M) | (19.09M) | (28.86M) | (39.90M) | (45.41M) | [{"date":"2019-12-31","value":-1667800000,"profit":false},{"date":"2020-12-31","value":-1908587400,"profit":false},{"date":"2021-12-31","value":-2885500000,"profit":false},{"date":"2022-12-31","value":-3990200000,"profit":false},{"date":"2023-12-31","value":-4541200000,"profit":false}] |
Total Non-Operating Income/Expense | 498.17K | (132.38K) | 828.00K | 2.78M | 7.77M | [{"date":"2019-12-31","value":6.41,"profit":true},{"date":"2020-12-31","value":-1.7,"profit":false},{"date":"2021-12-31","value":10.65,"profit":true},{"date":"2022-12-31","value":35.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (16.41M) | (19.31M) | (28.29M) | (38.70M) | (41.44M) | [{"date":"2019-12-31","value":-1641400000,"profit":false},{"date":"2020-12-31","value":-1930667200,"profit":false},{"date":"2021-12-31","value":-2829100000,"profit":false},{"date":"2022-12-31","value":-3870400000,"profit":false},{"date":"2023-12-31","value":-4144100000,"profit":false}] |
Income Taxes | (262.00K) | (26.73K) | (549.00K) | (1.20M) | 230.10K | [{"date":"2019-12-31","value":-113.86,"profit":false},{"date":"2020-12-31","value":-11.61,"profit":false},{"date":"2021-12-31","value":-238.59,"profit":false},{"date":"2022-12-31","value":-520.63,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (16.15M) | (19.28M) | (27.74M) | (37.51M) | (41.67M) | [{"date":"2019-12-31","value":-1615200000,"profit":false},{"date":"2020-12-31","value":-1927994700,"profit":false},{"date":"2021-12-31","value":-2774200000,"profit":false},{"date":"2022-12-31","value":-3750600000,"profit":false},{"date":"2023-12-31","value":-4167110500,"profit":false}] |
Income From Continuous Operations | (16.42M) | (19.28M) | (28.29M) | (38.70M) | (40.80M) | [{"date":"2019-12-31","value":-1641613700,"profit":false},{"date":"2020-12-31","value":-1927842800,"profit":false},{"date":"2021-12-31","value":-2829100000,"profit":false},{"date":"2022-12-31","value":-3870400000,"profit":false},{"date":"2023-12-31","value":-4080100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.15M) | (19.28M) | (27.74M) | (37.51M) | (41.44M) | [{"date":"2019-12-31","value":-1615200000,"profit":false},{"date":"2020-12-31","value":-1927994700,"profit":false},{"date":"2021-12-31","value":-2774200000,"profit":false},{"date":"2022-12-31","value":-3750600000,"profit":false},{"date":"2023-12-31","value":-4144100000,"profit":false}] |
EPS (Diluted) | (3.03) | (1.30) | (0.71) | (0.89) | (0.93) | [{"date":"2019-12-31","value":-303,"profit":false},{"date":"2020-12-31","value":-130,"profit":false},{"date":"2021-12-31","value":-71,"profit":false},{"date":"2022-12-31","value":-89,"profit":false},{"date":"2023-12-31","value":-93,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CRDF | |
---|---|
Cash Ratio | 4.60 |
Current Ratio | 4.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CRDF | |
---|---|
ROA (LTM) | -38.33% |
ROE (LTM) | -67.57% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CRDF | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.21 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.79 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CRDF | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 181.35 |
P/B | 2.39 |
Price/FCF | NM |
EV/R | 90.32 |
EV/Ebitda | NM |
Cardiff Oncology Inc (CRDF) share price today is $3.78
Yes, Indians can buy shares of Cardiff Oncology Inc (CRDF) on Vested. To buy Cardiff Oncology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRDF stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cardiff Oncology Inc (CRDF) via the Vested app. You can start investing in Cardiff Oncology Inc (CRDF) with a minimum investment of $1.
You can invest in shares of Cardiff Oncology Inc (CRDF) via Vested in three simple steps:
The 52-week high price of Cardiff Oncology Inc (CRDF) is $6.42. The 52-week low price of Cardiff Oncology Inc (CRDF) is $1.25.
The price-to-earnings (P/E) ratio of Cardiff Oncology Inc (CRDF) is
The price-to-book (P/B) ratio of Cardiff Oncology Inc (CRDF) is 2.39
The dividend yield of Cardiff Oncology Inc (CRDF) is 0.00%
The market capitalization of Cardiff Oncology Inc (CRDF) is $124.77M
The stock symbol (or ticker) of Cardiff Oncology Inc is CRDF